UNDERWRITING AGREEMENTUnderwriting Agreement • July 24th, 2023 • BioNexus Gene Lab Corp • Services-medical laboratories • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • July 17th, 2023 • BioNexus Gene Lab Corp • Services-medical laboratories • New York
Bionexus Gene Lab CorporationExecutive Employment Agreement • July 5th, 2023 • BioNexus Gene Lab Corp • Services-medical laboratories • Wyoming
This Executive Employment Agreement (the “Agreement”) is made and entered into as of the 19th day of June, 2017 and will be effective as of the 26th day of June, 2017 (the “Effective Date”), between Bionexus Gene Lab Corp, whose principal place of business is Unit 10-2, Tower B, Vertical Business Suite, Avenue 3 Bangsar South, No. 8, Jalan Kerinchi Kuala Lumpur, Malaysia (the “Company”) and Ms Wei Li Leong at 311 Lorong Maarof, Bukit Bandaraya, Bangsar, 59000 Kuala Lumpur, Malaysia (the “CFO”). This agreement supersedes all previous employment agreements as of the effective date. The Company is a Wyoming corporation and is principally engaged in the business of mRNA and infectious diseases screening (the “Business”). The Company desires to employ the CFO and the CFO desires to be employed by the Company, upon the terms and conditions hereinafter set forth.
Underwriter’s WarrantCommon Stock Purchase Warrant • July 24th, 2023 • BioNexus Gene Lab Corp • Services-medical laboratories • New York
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES BY HIS, HER OR ITS ACCEPTANCE HEREOF, THAT SUCH HOLDER WILL NOT FOR A PERIOD OF ONE HUNDRED EIGHTY (180) DAYS BEGINNING ON THE DATE OF COMMENCEMENT OF SALES OF THE OFFERING: (A) SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT OR THE SECURITIES ISSUABLE HEREUNDER TO ANYONE OTHER THAN OFFICERS OR PARTNERS OF NETWORK 1 FINANCIAL SECURITIES, INC., EACH OF WHOM SHALL HAVE AGREED TO THE RESTRICTIONS CONTAINED HEREIN, IN ACCORDANCE WITH FINRA CONDUCT RULE 5110(E), OR (B) CAUSE THIS PURCHASE WARRANT OR THE SECURITIES ISSUABLE HEREUNDER TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS PURCHASE WARRANT OR THE SECURITIES HEREUNDER, EXCEPT AS PROVIDED FOR IN FINRA RULE 5110(E)(2).
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • December 30th, 2020 • BioNexus Gene Lab Corp • Services-medical laboratories • Wyoming
This Agreement ("Agreement") is made and entered into this the 24th day of December 2020 by and between BioNexus Gene Lab Corp, a Wyoming company (the "BioNexus"), and Chemrex Corporation Sdn. Bhd., a Malaysian company ("Chemrex"), and the shareholders of the Chemrex identified on the signatory page of this Agreement (the "Chemrex Shareholders").
BIONEXUS GENE LAB CORPORATION Stock Grant AgreementStock Grant Agreement • October 15th, 2019 • BioNexus Gene Lab Coporation • Services-medical laboratories • Wyoming
